首页 > 最新文献

Revista espanola de medicina nuclear e imagen molecular最新文献

英文 中文
Expression of somatostatin receptors in lesions different from neuroendocrine tumors. 生长抑素受体在不同神经内分泌肿瘤中的表达。
Pub Date : 2025-12-11 DOI: 10.1016/j.remnie.2025.500265
C Pradère, K E Velázquez Díaz, I Garrido Solesio, A Grajeda Gallardo, P Manuel Meneses Soares, A Prieto Soriano, M Mitjavila Casanovas
{"title":"Expression of somatostatin receptors in lesions different from neuroendocrine tumors.","authors":"C Pradère, K E Velázquez Díaz, I Garrido Solesio, A Grajeda Gallardo, P Manuel Meneses Soares, A Prieto Soriano, M Mitjavila Casanovas","doi":"10.1016/j.remnie.2025.500265","DOIUrl":"https://doi.org/10.1016/j.remnie.2025.500265","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500265"},"PeriodicalIF":0.0,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SUMMARY: Selective Sentinel Lymph Node Biopsy (SSLNB) in breast cancer for residents. 摘要:选择性前哨淋巴结活检(SSLNB)在居民乳腺癌中的应用。
Pub Date : 2025-11-28 DOI: 10.1016/j.remnie.2025.500261
R Caratini, A Segarra, E Garcia, K Quintero, J Cordon, M Vega, J Cases, I Cebrecos, J Ribera-Perianes, S Vidal-Sicart

This work presents the key aspects of the sentinel lymph node biopsy (SLNB) procedure in breast cancer, based on the protocol used at Hospital Clínic de Barcelona. The aim is to facilitate its generalization in other hospital settings and training environments, promoting the standardization of the technique. It is also intended to serve as a useful resource for resident physicians and other medical trainees.

这项工作提出了乳腺癌前哨淋巴结活检(SLNB)程序的关键方面,基于Clínic de Barcelona医院使用的协议。目的是促进其在其他医院设置和培训环境的推广,促进技术的标准化。它还旨在为住院医师和其他医疗培训生提供有用的资源。
{"title":"SUMMARY: Selective Sentinel Lymph Node Biopsy (SSLNB) in breast cancer for residents.","authors":"R Caratini, A Segarra, E Garcia, K Quintero, J Cordon, M Vega, J Cases, I Cebrecos, J Ribera-Perianes, S Vidal-Sicart","doi":"10.1016/j.remnie.2025.500261","DOIUrl":"10.1016/j.remnie.2025.500261","url":null,"abstract":"<p><p>This work presents the key aspects of the sentinel lymph node biopsy (SLNB) procedure in breast cancer, based on the protocol used at Hospital Clínic de Barcelona. The aim is to facilitate its generalization in other hospital settings and training environments, promoting the standardization of the technique. It is also intended to serve as a useful resource for resident physicians and other medical trainees.</p>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500261"},"PeriodicalIF":0.0,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145650268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-depth clinical and dosimetric analysis of 166Ho-radioembolization in patients with liver cancer: An observational study. 肝癌患者166ho放射栓塞的深入临床和剂量学分析:一项观察性研究。
Pub Date : 2025-11-28 DOI: 10.1016/j.remnie.2025.500269
R Sá E Silva, J André Oliveira, J Santos, R Albergueiro, P Pereira, L Costa

Introduction: Transarterial radioembolization (TARE) using holmium-166 (¹⁶⁶Ho) microspheres is a treatment for unresectable primary and secondary liver malignancies. The pre-therapeutic simulation procedure using a scout dose is critical to predict microsphere distribution and exclude extrahepatic leakage. This single-center observational study aimed to evaluate the dosimetric agreement between ¹⁶⁶Ho-scout and ¹⁶⁶Ho-therapy, and to correlate tumor-absorbed dose with treatment response at both tumor and patient levels.

Methods: Prospective, observational study included patients with BCLC 2022 stage A/B hepatocellular carcinoma or oligometastatic liver disease undergoing ¹⁶⁶Ho-TARE were included. Voxel-based dosimetry was performed using Q-suite. Contrast-enhanced CT was acquired 3 months post-treatment. Treatment response was assessed by RECIST/mRECIST criteria.

Results: Twenty patients underwent the pre-treatment procedure; 18 proceeded to therapy. No significant differences were observed between scout and therapy procedures in whole-liver (P = .331) and tumor doses (P = .063), indicating reliable pre-therapeutic evaluation. Fourteen patients with 16 treated lesions were included in the dose-response analysis (median volume: 22,1 [10,5-80,3] mL; dose: 22,1 [10,5-80,3] Gy). The objective tumor response rate at 3 months was 94%. However, no significant differences were found in absorbed dose metrics (P = .315) or dose-volume histogram values (D50, D70, D85) between responsive and non-responsive (NR) lesions. Patient-level analysis showed a 29% progression rate, with NR patients more likely to have secondary liver tumors (P = .011).

Conclusion: This study including a Portuguese cohort treated with ¹⁶⁶Ho-TARE showed a high tumor response rate. However, the limited sample size reduces the robustness of the conclusions. Further data from ongoing follow-up are awaited.

简介:经动脉放射栓塞(TARE)使用钬-166微球是一种治疗不可切除的原发性和继发性肝脏恶性肿瘤的方法。使用侦察剂量的治疗前模拟程序对于预测微球分布和排除肝外渗漏至关重要。这项单中心观察性研究旨在评估¹⁶Ho-scout和¹⁶Ho-therapy之间的剂量学一致性,并在肿瘤和患者水平上将肿瘤吸收剂量与治疗反应联系起来。方法:前瞻性、观察性研究纳入BCLC 2022期A/B期肝细胞癌或寡转移性肝病患者,并接受Ho-TARE治疗。使用Q-suite进行基于体素的剂量测定。治疗后3个月行CT增强扫描。采用RECIST/mRECIST标准评估治疗反应。结果:20例患者完成了治疗前程序;18人接受治疗。在全肝(p=0.331)和肿瘤剂量(p=0.063)方面,scout和治疗方案之间无显著差异,表明治疗前评估可靠。14例16个治疗病灶的患者被纳入剂量-反应分析(中位容积:22,1 [10,5-80,3]mL;剂量:22,1 [10,5-80,3]Gy)。3个月客观肿瘤缓解率为94%。然而,在反应性和非反应性(NR)病变之间,吸收剂量指标(p=0.315)或剂量-体积直方图值(D50, D70, D85)没有发现显著差异。患者水平分析显示29%的进展率,NR患者更有可能发生继发性肝脏肿瘤(p=0.011)。结论:本研究包括一组葡萄牙队列患者,经¹⁶- Ho-TARE治疗后显示出较高的肿瘤缓解率。然而,有限的样本量降低了结论的稳健性。等待正在进行的后续行动的进一步数据。
{"title":"In-depth clinical and dosimetric analysis of <sup>166</sup>Ho-radioembolization in patients with liver cancer: An observational study.","authors":"R Sá E Silva, J André Oliveira, J Santos, R Albergueiro, P Pereira, L Costa","doi":"10.1016/j.remnie.2025.500269","DOIUrl":"10.1016/j.remnie.2025.500269","url":null,"abstract":"<p><strong>Introduction: </strong>Transarterial radioembolization (TARE) using holmium-166 (¹⁶⁶Ho) microspheres is a treatment for unresectable primary and secondary liver malignancies. The pre-therapeutic simulation procedure using a scout dose is critical to predict microsphere distribution and exclude extrahepatic leakage. This single-center observational study aimed to evaluate the dosimetric agreement between ¹⁶⁶Ho-scout and ¹⁶⁶Ho-therapy, and to correlate tumor-absorbed dose with treatment response at both tumor and patient levels.</p><p><strong>Methods: </strong>Prospective, observational study included patients with BCLC 2022 stage A/B hepatocellular carcinoma or oligometastatic liver disease undergoing ¹⁶⁶Ho-TARE were included. Voxel-based dosimetry was performed using Q-suite. Contrast-enhanced CT was acquired 3 months post-treatment. Treatment response was assessed by RECIST/mRECIST criteria.</p><p><strong>Results: </strong>Twenty patients underwent the pre-treatment procedure; 18 proceeded to therapy. No significant differences were observed between scout and therapy procedures in whole-liver (P = .331) and tumor doses (P = .063), indicating reliable pre-therapeutic evaluation. Fourteen patients with 16 treated lesions were included in the dose-response analysis (median volume: 22,1 [10,5-80,3] mL; dose: 22,1 [10,5-80,3] Gy). The objective tumor response rate at 3 months was 94%. However, no significant differences were found in absorbed dose metrics (P = .315) or dose-volume histogram values (D50, D70, D85) between responsive and non-responsive (NR) lesions. Patient-level analysis showed a 29% progression rate, with NR patients more likely to have secondary liver tumors (P = .011).</p><p><strong>Conclusion: </strong>This study including a Portuguese cohort treated with ¹⁶⁶Ho-TARE showed a high tumor response rate. However, the limited sample size reduces the robustness of the conclusions. Further data from ongoing follow-up are awaited.</p>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500269"},"PeriodicalIF":0.0,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145650683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research on quantitative assessment of renal tubular function based on renal dynamic imaging. 基于肾动态成像的肾小管功能定量评价研究。
Pub Date : 2025-11-28 DOI: 10.1016/j.remnie.2025.500268
W Liu, G Yao, Y Gao, C Wang

Objective: To establish a renal tubular uptake rate (RTUR) model based on renal dynamic imaging (RDI) for detecting early tubular injury and to explore its clinical application value.

Materials and methods: RDI data collected from August 2020 to June 2025 were analyzed. A total of 292 eligible cases (441 kidneys) were included. Participants were categorized into: - Control group: 56 cases (112 kidneys) - Renal insufficiency group: 93 cases (186 kidneys) - Fully compensated group: 62 cases (62 kidneys) - Partially compensated group: 35 cases (35 kidneys) - Decompensated group: 46 cases (46 kidneys).

Rtur calculation formula: RTUR = (Ascent slope of renal scintigraphy/Total injected radioactive drug activity) × 105 × 100%.

Analysis content: Distribution of RTUR values across five groups; correlation between GFR and RTUR in 441 kidneys. Differences in RTUR between the control group and other four groups; diagnostic efficacy and clinical value of RTUR.

Results: Compared with the control group, significant differences in RTUR were observed in the renal insufficiency group, fully compensated group, and decompensated group (P < .01). GFR in 441 kidneys showed a strong positive correlation with RTUR (r = 0.739, P < .001). ROC analysis indicated that RTUR ≤ 5.225% identified renal insufficiency (sensitivity 77.7%, specificity 70.4%), while RTUR ≥ 9.135% diagnosed complete renal compensation with 82.3% sensitivity.

Conclusion: The RTUR model enables stable quantitative assessment of renal tubular reabsorption rate, facilitating diagnosis of renal insufficiency and complete renal compensation. It holds promise as a novel quantitative indicator for evaluating tubular function. Renal GFR exhibits a strong correlation with RTUR.

目的:建立基于肾动态成像(RDI)的肾小管摄取率(RTUR)模型,用于早期检测肾小管损伤,并探讨其临床应用价值。材料与方法:对2020年8月至2025年6月收集的RDI数据进行分析。总共纳入292例符合条件的病例(441个肾脏)。参与者分为:-对照组:56例(112个肾脏)-肾功能不全组:93例(186个肾脏)-完全代偿组:62例(62个肾脏)-部分代偿组:35例(35个肾脏)-失代偿组:46例(46个肾脏)RTUR计算公式:RTUR =(肾扫描上升斜率/总注射放射性药物活性)×10 ×100%。分析内容:五组RTUR值分布;441个肾脏GFR与RTUR的相关性。对照组与其他四组RTUR的差异;RTUR的诊断效果及临床价值。结果:与对照组相比,肾功能不全组、完全代偿组和失代偿组的RTUR均有显著差异(P)。结论:RTUR模型能够稳定地定量评估肾小管重吸收率,有助于诊断肾功能不全和肾完全代偿。它有望成为评价肾小管功能的一种新的定量指标。肾GFR与RTUR有很强的相关性。
{"title":"Research on quantitative assessment of renal tubular function based on renal dynamic imaging.","authors":"W Liu, G Yao, Y Gao, C Wang","doi":"10.1016/j.remnie.2025.500268","DOIUrl":"10.1016/j.remnie.2025.500268","url":null,"abstract":"<p><strong>Objective: </strong>To establish a renal tubular uptake rate (RTUR) model based on renal dynamic imaging (RDI) for detecting early tubular injury and to explore its clinical application value.</p><p><strong>Materials and methods: </strong>RDI data collected from August 2020 to June 2025 were analyzed. A total of 292 eligible cases (441 kidneys) were included. Participants were categorized into: - Control group: 56 cases (112 kidneys) - Renal insufficiency group: 93 cases (186 kidneys) - Fully compensated group: 62 cases (62 kidneys) - Partially compensated group: 35 cases (35 kidneys) - Decompensated group: 46 cases (46 kidneys).</p><p><strong>Rtur calculation formula: </strong>RTUR = (Ascent slope of renal scintigraphy/Total injected radioactive drug activity) × 10<sup>5</sup> × 100%.</p><p><strong>Analysis content: </strong>Distribution of RTUR values across five groups; correlation between GFR and RTUR in 441 kidneys. Differences in RTUR between the control group and other four groups; diagnostic efficacy and clinical value of RTUR.</p><p><strong>Results: </strong>Compared with the control group, significant differences in RTUR were observed in the renal insufficiency group, fully compensated group, and decompensated group (P < .01). GFR in 441 kidneys showed a strong positive correlation with RTUR (r = 0.739, P < .001). ROC analysis indicated that RTUR ≤ 5.225% identified renal insufficiency (sensitivity 77.7%, specificity 70.4%), while RTUR ≥ 9.135% diagnosed complete renal compensation with 82.3% sensitivity.</p><p><strong>Conclusion: </strong>The RTUR model enables stable quantitative assessment of renal tubular reabsorption rate, facilitating diagnosis of renal insufficiency and complete renal compensation. It holds promise as a novel quantitative indicator for evaluating tubular function. Renal GFR exhibits a strong correlation with RTUR.</p>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500268"},"PeriodicalIF":0.0,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145649932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of differential renal function of children with urinary tract infection complicated by hydronephrosis using renal dynamic and static imaging techniques. 动态和静态肾显像技术对尿路感染并发肾积水患儿肾功能的鉴别评价。
Pub Date : 2025-11-27 DOI: 10.1016/j.remnie.2025.500260
X Ruan, H Wu, Z Chen

Objective: This study aims to compare differential renal function (DRF) results obtained from Tc-99m DTPA and Tc-99m DMSA scintigraphy in children with urinary tract infection (UTI) combined with varying degrees of hydronephrosis. We evaluate the diagnostic performance of both methods and provide recommendations for selecting individualized imaging strategies based on specific case characteristics.

Methods: A retrospective analysis was conducted on 57 children with UTI combined with ipsilateral hydronephrosis. Clinical data collected included gender, age, urinary ultrasound findings, and results from renal dynamic and static scintigraphy. Hydronephrosis was classified by ultrasound into mild (<15 mm), moderate (15-30 mm), and severe (>30 mm). The kidney volume ratio between the affected and unaffected sides was calculated. DRF percentages for each kidney were separately obtained from both scintigraphy methods, and the deviation in DRF of the affected kidney was calculated. Based on the degree of deviation, results were categorized as normal (<5%), differing (5%-10%), or significantly different (>10%). The non-parametric Mann-Whitney U test was used to compare DRF values between Tc-99m DMSA and Tc-99m DTPA. Spearman correlation analysis assessed the relationship between hydronephrosis and DRF deviation. Receiver operating characteristic (ROC) curves were used to determine diagnostic thresholds and assess the predictive value of renal pelvic and calyceal dilation for DRF deviations.

Results: Among the 57 children, the median DRF of the affected kidney was 50.84% (IQR: 43.24,55.00) by Tc-99m DMSA and45% (IQR: 35.35, 47.95) by Tc-99m DTPA, with the difference being statistically significant (Z = -4.074, p < 0.000). Of these, 34 children had a DRF deviation > 5%, and 16 had a deviation >10%. Positive correlations were observed between DRF deviation and renal pelvic dilation (r = 0.299, p = 0.024), calyceal dilation (r = 0.235, p = 0.078), and kidney volume ratio (r = 4.416, p = 0.001). A renal pelvic dilation >13.5 mm or calyceal dilation >8.8 mm predicted DRF deviations >5% with a sensitivity of 73.5% and 79.4%, respctively. For deviations >10%, a calyceal dilation long axis >23.2 mm yielded a diagnostic specificity of 100%.

Conclusion: Tc-99m DMSA-derived DRF may be affected by the degree of hydronephrosis. In children with UTI combined with hydronephrosis, significant differences in DRF assessment exist between Tc-99m DMSA and Tc-99m DTPA. When renal pelvic dilation exceeds 13.5 mm or calyceal diameter reaches 23.2 mm, Tc-99m DMSA may overestimate renal function. In such cases, Tc-99m DTPA should be considered for more accurate functional evaluation.

目的:本研究旨在比较Tc-99 m DTPA和Tc-99 m DMSA显像在尿路感染(UTI)合并不同程度肾积水患儿中的鉴别肾功能(DRF)结果。我们评估了这两种方法的诊断性能,并根据具体病例特征提供了选择个性化成像策略的建议。方法:对57例尿路感染合并同侧肾积水患儿进行回顾性分析。收集的临床资料包括性别、年龄、尿超音波表现,以及肾脏动态和静态显像结果。超声将肾积水分为轻度(30mm)。计算受累侧与未受累侧肾脏体积比。通过两种闪烁成像方法分别获得每个肾脏的DRF百分比,并计算受影响肾脏的DRF偏差。根据偏差程度,将结果归类为正常(10%)。采用非参数Mann-Whitney U检验比较Tc-99 m DMSA和Tc-99 m DTPA之间的DRF值。Spearman相关分析评估肾积水与DRF偏差的关系。采用受试者工作特征(ROC)曲线确定诊断阈值,并评估肾盆腔和肾盏扩张对DRF偏差的预测价值。结果:57例患儿中,Tc-99 m DMSA的中位DRF为50.84% (IQR: 43.24,55.00), Tc-99 m DTPA的中位DRF为45% (IQR: 35.35, 47.95),差异有统计学意义(Z = -4.074, p < 5%), 16例患儿偏差为0.10%。DRF偏差与肾盆腔扩张(r = 0.299, p = 0.024)、肾盏扩张(r = 0.235, p = 0.078)、肾体积比(r = 4.416, p = 0.001)呈正相关。肾盆腔扩张b> 13.5 mm或肾盏扩张b> 8.8 mm预测DRF偏差b> 5%,敏感性分别为73.5%和79.4%。对于偏差>0 %,肾盏扩张长轴>23.2 mm的诊断特异性为100%。结论:tc - 99mdmsa衍生DRF可能受肾积水程度的影响。在UTI合并肾积水的儿童中,Tc-99 m DMSA和Tc-99 m DTPA在DRF评估上存在显著差异。当肾盆腔扩张超过13.5 mm或肾盏直径达到23.2 mm时,Tc-99 m DMSA可能会高估肾功能。在这种情况下,应该考虑使用tc - 99m DTPA进行更准确的功能评估。
{"title":"Evaluation of differential renal function of children with urinary tract infection complicated by hydronephrosis using renal dynamic and static imaging techniques.","authors":"X Ruan, H Wu, Z Chen","doi":"10.1016/j.remnie.2025.500260","DOIUrl":"10.1016/j.remnie.2025.500260","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to compare differential renal function (DRF) results obtained from Tc-99m DTPA and Tc-99m DMSA scintigraphy in children with urinary tract infection (UTI) combined with varying degrees of hydronephrosis. We evaluate the diagnostic performance of both methods and provide recommendations for selecting individualized imaging strategies based on specific case characteristics.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 57 children with UTI combined with ipsilateral hydronephrosis. Clinical data collected included gender, age, urinary ultrasound findings, and results from renal dynamic and static scintigraphy. Hydronephrosis was classified by ultrasound into mild (<15 mm), moderate (15-30 mm), and severe (>30 mm). The kidney volume ratio between the affected and unaffected sides was calculated. DRF percentages for each kidney were separately obtained from both scintigraphy methods, and the deviation in DRF of the affected kidney was calculated. Based on the degree of deviation, results were categorized as normal (<5%), differing (5%-10%), or significantly different (>10%). The non-parametric Mann-Whitney U test was used to compare DRF values between Tc-99m DMSA and Tc-99m DTPA. Spearman correlation analysis assessed the relationship between hydronephrosis and DRF deviation. Receiver operating characteristic (ROC) curves were used to determine diagnostic thresholds and assess the predictive value of renal pelvic and calyceal dilation for DRF deviations.</p><p><strong>Results: </strong>Among the 57 children, the median DRF of the affected kidney was 50.84% (IQR: 43.24,55.00) by Tc-99m DMSA and45% (IQR: 35.35, 47.95) by Tc-99m DTPA, with the difference being statistically significant (Z = -4.074, p < 0.000). Of these, 34 children had a DRF deviation > 5%, and 16 had a deviation >10%. Positive correlations were observed between DRF deviation and renal pelvic dilation (r = 0.299, p = 0.024), calyceal dilation (r = 0.235, p = 0.078), and kidney volume ratio (r = 4.416, p = 0.001). A renal pelvic dilation >13.5 mm or calyceal dilation >8.8 mm predicted DRF deviations >5% with a sensitivity of 73.5% and 79.4%, respctively. For deviations >10%, a calyceal dilation long axis >23.2 mm yielded a diagnostic specificity of 100%.</p><p><strong>Conclusion: </strong>Tc-99m DMSA-derived DRF may be affected by the degree of hydronephrosis. In children with UTI combined with hydronephrosis, significant differences in DRF assessment exist between Tc-99m DMSA and Tc-99m DTPA. When renal pelvic dilation exceeds 13.5 mm or calyceal diameter reaches 23.2 mm, Tc-99m DMSA may overestimate renal function. In such cases, Tc-99m DTPA should be considered for more accurate functional evaluation.</p>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500260"},"PeriodicalIF":0.0,"publicationDate":"2025-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Feasibility of transperineal prostate biopsy guided by fusion of [18F]F-PSMA-1007 PET/MRI with real-time transrectal ultrasound. Prostate cancer classification using imaging biomarkers and radiomics in PIRADS 3 lesions. [18F]F-PSMA-1007 PET/MRI与实时经直肠超声融合引导下经会阴前列腺活检的可行性影像学生物标志物和放射组学在PIRADS 3病变中的前列腺癌分类。
Pub Date : 2025-11-27 DOI: 10.1016/j.remnie.2025.500263
J R Garcia, N Garrido, P Bassa, A Compte, L Pinilla, J A Romero, L L Mont, J Garcia, S Ruiz, S Mourelo, J M Santabárbara, E Riera

Objective: To assess the diagnostic feasibility of transperineal biopsy guided by fusion of PET/MRI with [18F]F-PSMA-1007 and real-time transrectal ultrasound (BP PET/MR PSMA + TRUS) in patients with PIRADS 3 lesions. To analyze imaging biomarkers and radiomic features for differentiating between patients with negative biopsy, clinically non-significant prostate cancer (cnsPCa), and clinically significant prostate cancer (csPCa).

Methods: A prospective study was conducted in 20 patients with PIRADS 3 lesions and PSA ≥ 4 ng/mL, with no concurrent suspicious lesions. All patients underwent a PET/MRI with [18F]F-PSMA-1007, followed by targeted biopsy using real-time ultrasound fusion. Diagnostic accuracy for prostate cancer (PCa) and the proportion of csPCa and cnsPCa diagnoses were calculated. Imaging biomarkers and machine learning models based on radiomic features were analyzed.

Results: The technique was feasible in 100% of cases. The overall detection rate of PCa was 80%, with 100% sensitivity and 36% specificity for csPCa. SUVpeak was the only biomarker that showed significant differences between patients with negative histology and PCa (AUC 0.81; sensitivity 75%; specificity 80%; cutoff value 3.5). No biomarker successfully differentiated between csPCa and cnsPCa. Both supervised classification models demonstrated high diagnostic performance (AUC > 0.95): Multimodal regression performed slightly better for binary classification (negative vs. PCa). Random Forest outperformed in three-class classification (negative vs. cnsPCa vs. csPCa).

Conclusions: BP PET/MRI PSMA + TRUS is a feasible, safe, and potentially superior technique compared to MRI-only targeted biopsy, especially in PIRADS 3 lesions. Radiomic analysis improves discriminative ability over conventional imaging biomarkers, particularly for distinguishing between cnsPCa and csPCa.

目的:评价PET/MRI联合[18F]F-PSMA-1007与实时经直肠超声(BP PET/MR PSMA + TRUS)融合引导下经会阴活检对PIRADS 3型病变的诊断可行性。分析活检阴性、临床无显著性前列腺癌(cnsPCa)和临床显著性前列腺癌(csPCa)患者的影像学生物标志物和放射学特征。方法:前瞻性研究20例PIRADS 3病变,PSA≥4 ng/ml,无并发可疑病变的患者。所有患者均接受PET/MRI检查[18F]F-PSMA-1007,然后采用实时超声融合进行靶向活检。计算前列腺癌(PCa)的诊断准确率以及csPCa和cnsPCa的诊断比例。分析了基于放射学特征的成像生物标志物和机器学习模型。结果:该方法100%可行。PCa的总检出率为80%,csPCa的敏感性为100%,特异性为36%。SUVpeak是唯一在组织学阴性患者和PCa患者之间显示有显著差异的生物标志物(AUC 0.81,敏感性75%,特异性80%,临界值3.5)。没有生物标志物成功区分csPCa和cnsPCa。两种监督分类模型都表现出较高的诊断性能(AUC > 0.95):多模态回归在二元分类方面表现略好(与PCa相比为负)。随机森林在三类分类(阴性vs. cnsPCa vs. csPCa)中表现较好。结论:BP PET/MRI PSMA + TRUS是一种可行的、安全的、潜在的优于仅MRI靶向活检的技术,特别是在PIRADS 3病变中。放射组学分析提高了传统成像生物标志物的鉴别能力,特别是在区分cnsPCa和csPCa方面。
{"title":"Feasibility of transperineal prostate biopsy guided by fusion of [18F]F-PSMA-1007 PET/MRI with real-time transrectal ultrasound. Prostate cancer classification using imaging biomarkers and radiomics in PIRADS 3 lesions.","authors":"J R Garcia, N Garrido, P Bassa, A Compte, L Pinilla, J A Romero, L L Mont, J Garcia, S Ruiz, S Mourelo, J M Santabárbara, E Riera","doi":"10.1016/j.remnie.2025.500263","DOIUrl":"10.1016/j.remnie.2025.500263","url":null,"abstract":"<p><strong>Objective: </strong>To assess the diagnostic feasibility of transperineal biopsy guided by fusion of PET/MRI with [18F]F-PSMA-1007 and real-time transrectal ultrasound (BP PET/MR PSMA + TRUS) in patients with PIRADS 3 lesions. To analyze imaging biomarkers and radiomic features for differentiating between patients with negative biopsy, clinically non-significant prostate cancer (cnsPCa), and clinically significant prostate cancer (csPCa).</p><p><strong>Methods: </strong>A prospective study was conducted in 20 patients with PIRADS 3 lesions and PSA ≥ 4 ng/mL, with no concurrent suspicious lesions. All patients underwent a PET/MRI with [18F]F-PSMA-1007, followed by targeted biopsy using real-time ultrasound fusion. Diagnostic accuracy for prostate cancer (PCa) and the proportion of csPCa and cnsPCa diagnoses were calculated. Imaging biomarkers and machine learning models based on radiomic features were analyzed.</p><p><strong>Results: </strong>The technique was feasible in 100% of cases. The overall detection rate of PCa was 80%, with 100% sensitivity and 36% specificity for csPCa. SUVpeak was the only biomarker that showed significant differences between patients with negative histology and PCa (AUC 0.81; sensitivity 75%; specificity 80%; cutoff value 3.5). No biomarker successfully differentiated between csPCa and cnsPCa. Both supervised classification models demonstrated high diagnostic performance (AUC > 0.95): Multimodal regression performed slightly better for binary classification (negative vs. PCa). Random Forest outperformed in three-class classification (negative vs. cnsPCa vs. csPCa).</p><p><strong>Conclusions: </strong>BP PET/MRI PSMA + TRUS is a feasible, safe, and potentially superior technique compared to MRI-only targeted biopsy, especially in PIRADS 3 lesions. Radiomic analysis improves discriminative ability over conventional imaging biomarkers, particularly for distinguishing between cnsPCa and csPCa.</p>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500263"},"PeriodicalIF":0.0,"publicationDate":"2025-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of post-PTE pulmonary reperfusion using automatic segmentation and quantitative analysis of lung perfusion SPECT/CT. 应用肺灌注SPECT/CT自动分割定量分析评价pte后肺再灌注。
Pub Date : 2025-11-27 DOI: 10.1016/j.remnie.2025.500262
N Álvarez Mena, F Sebastián Palacid, B Pérez López, S Pena Vaquero, A E Hurtado Romero, R C Zambrano Infantino, R Ruano Pérez

Objective: To assess the diagnostic impact of using automatic segmentation and quantitative analysis of lung perfusion SPECT/CT in the evaluation of pulmonary reperfusion in patients undergoing follow-up for pulmonary thromboembolism (PTE).

Materials and methods: A prospective study was conducted from October 2021 to October 2024. We included 132 patients with PTE diagnosed by lung perfusion scintigraphy with SPECT/CT, who underwent a follow-up scan at 6 months. Reperfusion was assessed visually and quantitatively. Three grades were visually established: no reperfusion, partial reperfusion, and complete reperfusion. For quantitative analysis, automatic segmentation was performed, obtaining volumes and total counts in the baseline and follow-up SPECT/CT scans. Two parameters were established for comparison: the relative decrease in defect volume (RDV) and the relative increase in total perfused volume counts (RIC). Reperfusion was classified as: no reperfusion, partial reperfusion (minor and major), and complete reperfusion. The scintigraphic results were correlated with demographic variables, extension and size of the PTE and other complementary diagnostic tools (pulmonary function tests and echocardiogram).

Results: 82 patients were women (mean age 70 ± 16 years) and 50 were men (64 ± 15 years). Comparing the agreement between visual and quantitative analysis (weighted Cohen's Kappa index), a slight, but non-statistically significant, agreement was demonstrated between evaluators (κ = 0.04; p = 0.464). Pearson's assessment revealed a very high and positive assessment between RDV and RIC (r = 0.77; p < 0.001). Patients with abnormal complementary diagnostics tools at follow-up were not more likely to have residual thrombosis (p > 0.05 in the visual and quantitative analyses). The remaining variables also did not show statistical significance in the persistence of PTE.

Conclusions: In the assessment of post-PTE pulmonary reperfusion, quantitative analysis of lung perfusion SPECT/CT is superior to visual analysis. Furthermore, it suggests that it is a particularly useful tool in patients in whom visual analysis does not show improvement, as it could prevent unnecessary and prolonged treatment if reperfusion is observed through quantification.

目的:评价肺灌注SPECT/CT自动分割定量分析在肺血栓栓塞(PTE)随访患者肺再灌注评价中的诊断价值。材料与方法:前瞻性研究于2021年10月至2024年10月进行。我们纳入了132例经SPECT/CT肺灌注显像诊断为PTE的患者,他们在6个月时接受了随访扫描。目视定量评估再灌注。视觉上分为三个等级:无再灌注、部分再灌注和完全再灌注。为了进行定量分析,进行自动分割,获得基线和随访SPECT/CT扫描中的体积和总数。建立缺陷体积(RDV)相对减少和总灌注体积计数(RIC)相对增加两个参数进行比较。再灌注分为:无再灌注、部分再灌注(轻度和重度)、完全再灌注。扫描结果与人口统计学变量、PTE的延伸和大小以及其他辅助诊断工具(肺功能检查和超声心动图)相关。结果:女性82例,平均年龄70±16岁;男性50例,平均年龄64±15岁。比较视觉分析和定量分析之间的一致性(加权Cohen's Kappa指数),评估者之间存在轻微但无统计学意义的一致性(κ = 0.04; p = 0.464)。Pearson评估显示RDV和RIC之间存在非常高的阳性评估(r = 0.77;目视和定量分析p 0.05)。结论:在评估pte后肺再灌注时,定量分析肺灌注SPECT/CT优于目测分析。此外,该研究表明,对于视觉分析没有显示改善的患者,它是一个特别有用的工具,因为如果通过定量观察再灌注,它可以防止不必要的和延长的治疗。
{"title":"Assessment of post-PTE pulmonary reperfusion using automatic segmentation and quantitative analysis of lung perfusion SPECT/CT.","authors":"N Álvarez Mena, F Sebastián Palacid, B Pérez López, S Pena Vaquero, A E Hurtado Romero, R C Zambrano Infantino, R Ruano Pérez","doi":"10.1016/j.remnie.2025.500262","DOIUrl":"10.1016/j.remnie.2025.500262","url":null,"abstract":"<p><strong>Objective: </strong>To assess the diagnostic impact of using automatic segmentation and quantitative analysis of lung perfusion SPECT/CT in the evaluation of pulmonary reperfusion in patients undergoing follow-up for pulmonary thromboembolism (PTE).</p><p><strong>Materials and methods: </strong>A prospective study was conducted from October 2021 to October 2024. We included 132 patients with PTE diagnosed by lung perfusion scintigraphy with SPECT/CT, who underwent a follow-up scan at 6 months. Reperfusion was assessed visually and quantitatively. Three grades were visually established: no reperfusion, partial reperfusion, and complete reperfusion. For quantitative analysis, automatic segmentation was performed, obtaining volumes and total counts in the baseline and follow-up SPECT/CT scans. Two parameters were established for comparison: the relative decrease in defect volume (RDV) and the relative increase in total perfused volume counts (RIC). Reperfusion was classified as: no reperfusion, partial reperfusion (minor and major), and complete reperfusion. The scintigraphic results were correlated with demographic variables, extension and size of the PTE and other complementary diagnostic tools (pulmonary function tests and echocardiogram).</p><p><strong>Results: </strong>82 patients were women (mean age 70 ± 16 years) and 50 were men (64 ± 15 years). Comparing the agreement between visual and quantitative analysis (weighted Cohen's Kappa index), a slight, but non-statistically significant, agreement was demonstrated between evaluators (κ = 0.04; p = 0.464). Pearson's assessment revealed a very high and positive assessment between RDV and RIC (r = 0.77; p < 0.001). Patients with abnormal complementary diagnostics tools at follow-up were not more likely to have residual thrombosis (p > 0.05 in the visual and quantitative analyses). The remaining variables also did not show statistical significance in the persistence of PTE.</p><p><strong>Conclusions: </strong>In the assessment of post-PTE pulmonary reperfusion, quantitative analysis of lung perfusion SPECT/CT is superior to visual analysis. Furthermore, it suggests that it is a particularly useful tool in patients in whom visual analysis does not show improvement, as it could prevent unnecessary and prolonged treatment if reperfusion is observed through quantification.</p>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500262"},"PeriodicalIF":0.0,"publicationDate":"2025-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors of a response to radioactive iodine therapy in hyperthyroidism - ablative dose concept: A 23-year single center 914-patient experience. 甲状腺机能亢进患者对放射性碘治疗反应的预测因素-消融剂量概念:一项23年914例单中心患者经验。
Pub Date : 2025-11-27 DOI: 10.1016/j.remnie.2025.500264
N Pantic, J Petrovic, S Odalovic, D Sobic Saranovic, M Kotur, L Grujicic, J Zivanovic, J Pantovic, I Grozdic Milojevic, V Artiko, B Radovic

Objective: The three treatment modalities for patients with hyperthyroidism are antithyroid drugs (ATDs), surgery, and radioactive iodine (RAI) therapy. The study aims to determine the predictors of a response to RAI in patients with hyperthyroidism.

Materials and methods: We retrospectively assessed 914 patients who received RAI for the treatment of hyperthyroidism between January 2000 and December 2023, with a follow-up of at least 6 months after the first dose.

Results: Hypothyroidism was ultimately achieved in 62.9% of the patients. Multiple variables are possible predictors in univariable logistic regression analysis. However, only shorter duration of ATD therapy (odds ratio 0.996; 95% confidence interval [CI], 0.093-0.999; P = .003, multivariable logistic regression analysis) and a diagnosis of Graves' disease (GD) (odds ratio 1.803; 95% confidence interval [CI], 1.042-3.141; P = .035, multivariable logistic regression analysis) are the independent predictors of post-treatment hypothyroidism, with decreasing age also being a late-response independent predictor of hypothyroidism 24 months after the treatment (odds ratio 0.983; 95% confidence interval [CI], 0.968-0.998; P = .028, multivariable logistic regression analysis). The median time to hypothyroidism was 10.0 ± 0.7 months (Kaplan-Meier method), with a statistically significant difference in hypothyroidism-free survival (HFS) between patients with GD on one side and solitary toxic adenoma (STA) and toxic multinodular goiter (TMG) on the other (P < .001, log-rank test).

Conclusions: GD and a shorter duration of previous ATD therapy are independent predictors of post-therapeutic hypothyroidism in patients treated for hyperthyroidism with RAI, with younger age also being an independent predictor of a late response.

目的:抗甲状腺药物(ATDs)、手术治疗和放射性碘(RAI)治疗是甲状腺功能亢进患者的三种治疗方式。该研究旨在确定甲状腺功能亢进患者对RAI反应的预测因素。材料和方法:我们回顾性评估了2000年1月至2023年12月期间接受RAI治疗甲状腺功能亢进的914例患者,首次给药后随访至少6个月。结果:62.9%的患者最终实现甲状腺功能减退。在单变量logistic回归分析中,多变量是可能的预测因子。然而,只有较短的ATD治疗时间(优势比0.996,95%可信区间[CI], 0.093-0.999, p = 0.003,多变量logistic回归分析)和诊断为Graves病(GD)(优势比1.803,95%可信区间[CI], 1.042-3.141;p = 0.035,多变量logistic回归分析)是治疗后甲状腺功能减退的独立预测因子,年龄下降也是治疗后24个月甲状腺功能减退的晚期反应独立预测因子(优势比0.983;95%可信区间[CI], 0.968 ~ 0.998; p = 0.028,多变量logistic回归分析)。发生甲状腺功能减退的中位时间为10.0 +/- 0.7个月(Kaplan-Meier法),单侧GD患者与单侧中毒性腺瘤(STA)、中毒性多结节性甲状腺肿(TMG)患者无甲状腺功能减退生存期(HFS)差异有统计学意义(p)。GD和既往ATD治疗持续时间较短是RAI治疗甲状腺功能亢进患者治疗后甲状腺功能减退的独立预测因素,年龄较小也是延迟反应的独立预测因素。
{"title":"Predictors of a response to radioactive iodine therapy in hyperthyroidism - ablative dose concept: A 23-year single center 914-patient experience.","authors":"N Pantic, J Petrovic, S Odalovic, D Sobic Saranovic, M Kotur, L Grujicic, J Zivanovic, J Pantovic, I Grozdic Milojevic, V Artiko, B Radovic","doi":"10.1016/j.remnie.2025.500264","DOIUrl":"10.1016/j.remnie.2025.500264","url":null,"abstract":"<p><strong>Objective: </strong>The three treatment modalities for patients with hyperthyroidism are antithyroid drugs (ATDs), surgery, and radioactive iodine (RAI) therapy. The study aims to determine the predictors of a response to RAI in patients with hyperthyroidism.</p><p><strong>Materials and methods: </strong>We retrospectively assessed 914 patients who received RAI for the treatment of hyperthyroidism between January 2000 and December 2023, with a follow-up of at least 6 months after the first dose.</p><p><strong>Results: </strong>Hypothyroidism was ultimately achieved in 62.9% of the patients. Multiple variables are possible predictors in univariable logistic regression analysis. However, only shorter duration of ATD therapy (odds ratio 0.996; 95% confidence interval [CI], 0.093-0.999; P = .003, multivariable logistic regression analysis) and a diagnosis of Graves' disease (GD) (odds ratio 1.803; 95% confidence interval [CI], 1.042-3.141; P = .035, multivariable logistic regression analysis) are the independent predictors of post-treatment hypothyroidism, with decreasing age also being a late-response independent predictor of hypothyroidism 24 months after the treatment (odds ratio 0.983; 95% confidence interval [CI], 0.968-0.998; P = .028, multivariable logistic regression analysis). The median time to hypothyroidism was 10.0 ± 0.7 months (Kaplan-Meier method), with a statistically significant difference in hypothyroidism-free survival (HFS) between patients with GD on one side and solitary toxic adenoma (STA) and toxic multinodular goiter (TMG) on the other (P < .001, log-rank test).</p><p><strong>Conclusions: </strong>GD and a shorter duration of previous ATD therapy are independent predictors of post-therapeutic hypothyroidism in patients treated for hyperthyroidism with RAI, with younger age also being an independent predictor of a late response.</p>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500264"},"PeriodicalIF":0.0,"publicationDate":"2025-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metastatic retroperitoneal paraganglioma: Insights from somatostatin receptor versus FAPI imaging. 转移性腹膜后副神经节瘤:来自生长抑素受体与FAPI成像的见解。
Pub Date : 2025-11-27 DOI: 10.1016/j.remnie.2025.500266
M H Samadi, P Sahafi, M Ahmadi, A Taghizadeh, A Aghaee
{"title":"Metastatic retroperitoneal paraganglioma: Insights from somatostatin receptor versus FAPI imaging.","authors":"M H Samadi, P Sahafi, M Ahmadi, A Taghizadeh, A Aghaee","doi":"10.1016/j.remnie.2025.500266","DOIUrl":"10.1016/j.remnie.2025.500266","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500266"},"PeriodicalIF":0.0,"publicationDate":"2025-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FDG PET/CT reveals solitary hepatic metastasis from urachal adenocarcinoma mimicking a hepatic pseudolesion on contrast-enhanced CT. FDG PET/CT在增强CT上显示尿管腺癌的孤立性肝转移,类似肝脏假性变。
Pub Date : 2025-11-26 DOI: 10.1016/j.remnie.2025.500259
D Huang, C Jiang, Z He, Y Chen
{"title":"FDG PET/CT reveals solitary hepatic metastasis from urachal adenocarcinoma mimicking a hepatic pseudolesion on contrast-enhanced CT.","authors":"D Huang, C Jiang, Z He, Y Chen","doi":"10.1016/j.remnie.2025.500259","DOIUrl":"10.1016/j.remnie.2025.500259","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500259"},"PeriodicalIF":0.0,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista espanola de medicina nuclear e imagen molecular
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1